RecruitingNCT05943522
Asciminib RMP Study
A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
Sponsor
Novartis Pharmaceuticals
Enrollment
100 participants
Start Date
Jul 19, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria2
- Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
- Patients who are willing to provide written informed consent prior to study enrollment
Exclusion Criteria2
- Patients with contraindication according to locally approved label of Scemblix®
- Patients who receive or are going to receive any investigational medicine during the observation period
Interventions
OTHERAsciminib
There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05943522
Related Trials
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT0699467611 locations
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
NCT062298601 location
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
NCT062367241 location
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069740 locations
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT068177201 location